538 related articles for article (PubMed ID: 25466561)
1. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
2. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
4. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
[TBL] [Abstract][Full Text] [Related]
6. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
7. Effects of eplerenone versus losartan in patients with low-renin hypertension.
Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
9. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
Danjuma MI; Mukherjee I; Makaronidis J; Osula S
Curr Hypertens Rep; 2014 Feb; 16(2):414. PubMed ID: 24407447
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
Pelliccia F; Patti G; Rosano G; Greco C; Gaudio C
Int J Cardiol; 2014 Nov; 177(1):219-28. PubMed ID: 25499383
[TBL] [Abstract][Full Text] [Related]
15. Eplerenone for hypertension.
Tam TS; Wu MH; Masson SC; Tsang MP; Stabler SN; Kinkade A; Tung A; Tejani AM
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008996. PubMed ID: 28245343
[TBL] [Abstract][Full Text] [Related]
16. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
[TBL] [Abstract][Full Text] [Related]
17. [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Derer W; Dechend R; Müller DN
MMW Fortschr Med; 2010 Feb; 152(6):48-9. PubMed ID: 20302183
[No Abstract] [Full Text] [Related]
18. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
